Clinical trials: Tocilizumab, open to volunteers
Giant Cell Arteritis (GCA)
Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
This is a multi-center, randomized, open label study that will assess the efficacy and safety of ACTEMRA(R) or one of its FDA-approved biosimilars Tocilizumab (TCZ) maintenance versus withdrawal in Giant cell arteritis (GCA)…
- Trial name
- NCT07108387
- Testing
- Tocilizumab, Discontinue Tocilizumab
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Over half of women in the US who are breastfeeding their infants take prescription drugs. You are being asked to participate in this study because you are breastfeeding your infant and are currently taking, as part of your…
- Trial name
- NCT03511118
- Testing
- Tranexamic acid (TXA), labetalol, metformin
- Where
- 22 sites in United States, Canada
- Volunteers
- 1,600 people
- Sponsor
- Duke University
Arthritis, Rheumatoid
Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
The goal of this N-of-1 study is to learn about treatment for individual patients who have rheumatoid arthritis (RA,) for which many treatments are available.
- Trial name
- NCT06016517
- Testing
- Etanercept, Adalimumab, Upadacitinib
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Tufts Medical Center
AQP4+ NMOSD
A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients
The goal of this clinical trial is to find out if the investigational medicine BMS-986353 is safe and well tolerated in adults with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- NCT07573332
- Testing
- CC-97540 (BMS-986353), Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Texas Southwestern Medical Center
Calciphylaxis
Anti-Interleukin-6 (IL6) in Calciphylaxis
Calciphylaxis is a rare but incredibly dangerous condition that causes small blood vessels in the skin to become blocked by calcium buildup and blood clots. This leads to painful skin sores (necrosis) that do not heal easily.
- Trial name
- NCT07708038
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Boston Medical Center
Refractory Autoimmune Diseases
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory…
- Trial name
- NCT07115745
- Testing
- BMS-986515, Fludarabine, Cyclophosphamide
- Where
- 28 sites in United States, Australia and 8 more
- Volunteers
- 125 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Rheumatic Disease
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating…
- Trial name
- NCT07138898
- Testing
- Methotrexate, Sulfasalazine, Hydroxychloroquine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- NYU Langone Health
Sickle Cell Disease, Acute Chest Syndrome
Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease
The purpose of this study is to determine whether a single infusion of tocilizumab is effective in reducing the time to successful weaning from both supplemental oxygen and any respiratory support, in pediatric and adult patients…
- Trial name
- TOCIACS (NCT06818266)
- Testing
- Tocilizumab (RoActemra®, 20 mg/mL).
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Prostate Adenocarcinoma, Prostate Cancer
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
This phase II trial studies how well atezolizumab works alone or in combination with etrumadenant or tocilizumab in treating men with localized prostate cancer before radical prostatectomy.
- Conditions
- Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer
- Trial name
- NCT03821246
- Testing
- Atezolizumab, Tocilizumab, Etrumadenant
- Where
- 2 sites in United States
- Volunteers
- 68 people
- Sponsor
- David Oh
Granulomatous Lobular Mastitis, Granulomatous Mastitis
Tocilizumab for the Treatment of Refractory Granulomatous Lobular Mastitis
Non-Lactational Granulomatous Lobular Mastitis (NL-GLM) is an inflammatory disease of unknown etiology, characterized clinically by local breast masses, accompanied by redness and swelling of the overlying skin, sinus tract…
- Trial name
- NCT07595900
- Testing
- Tocilizumab
- Volunteers
- 31 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Treatment-Resistant Major Depressive Disorder
Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)
Clinical trial aimed at evaluating whether a single infusion of tocilizumab, a medication that blocks the action of an inflammatory molecule called interleukin-6 (IL-6), can reduce symptoms of treatment-resistant major depression…
- Trial name
- NCT07052058
- Testing
- Tocilizumab, Normal Saline (0.9% NaCl)
- Where
- Brazil
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hospital de Clinicas de Porto Alegre
Major Depressive Disorder
Neutralizing Interleukin (IL)-6
The proposed study aims to establish the feasibility and safety of subcutaneous tocilizumab, a monoclonal antibody (mAb) against interleukin (IL)-6 receptor, in adults with Major Depressive Disorder (MDD) and evidence of…
- Trial name
- NCT07493317
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) Juvenile Idiopathic Arthritis.
- Trial name
- NCT05233397
- Testing
- Tocilizumab
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 30 people
- Sponsor
- Nationwide Children's Hospital
Multiple Myeloma
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
- Trial name
- NCT05972135
- Testing
- Teclistamab, Talquetamab, Tocilizumab
- Where
- 17 sites in United States
- Volunteers
- 100 people
- Sponsor
- SCRI Development Innovations, LLC
Pneumonia
Randomised Evaluation of COVID-19 Therapy
RECOVERY is a randomised trial of treatments to prevent death in patients hospitalised with pneumonia. The treatments being investigated are: COVID-19: Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin…
- Trial name
- RECOVERY (NCT04381936)
- Testing
- Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine
- Where
- 16 sites in Belgium, Estonia and 14 more
- Volunteers
- 70,000 people
- Sponsor
- University of Oxford
Systemic Sclerosis, Interstitial Lung Disease
Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
The study includes adult patients with systemic sclerosis (SSc) with interstitial lung disease (ILD) to evaluate the efficacy and safety of nintedanib plus tocilizumab combination therapy compared to standard therapy…
- Trial name
- NINTOC-TU (NCT06297096)
- Testing
- Tocilizumab, Nintedanib, Standard therapy
- Where
- Poland
- Volunteers
- 86 people
- Sponsor
- National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
The purpose of this study is to identify the most promising therapeutic strategy for patients with granulomatosis with polyangiitis and inadequate response to standard of care therapy.
- Trial name
- SATELITE (NCT04871191)
- Testing
- Rituximab, Tocilizumab, Tofacitinib
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Takayasu Arteritis
Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission
Takayasu arteritis is a chronic large-vessel vasculitis affecting the aorta and its major branches. Biologic therapies such as tumor necrosis factor inhibitors and tocilizumab are commonly used in patients with refractory or…
- Trial name
- NCT07491913
- Testing
- Tociliuzumab, Infliximab, Adalimumab
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Marmara University
Leukemia Acute Myeloid - AML
Study With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia
This is a phase 1, open label, interventional, single center, in patients with Acute Myeloid Leukemia (AML). This study will investigate dose escalation of tocilizumab in combination with venetoclax and azacitidine chemotherapy.
- Trial name
- TOCIVENA (NCT07392814)
- Testing
- increase dose of tocilizumab
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Nantes University Hospital
Kidney Transplant Rejection
Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab
Chronic active antibody mediated rejection (CAMR) is a therapeutic challenge in transplant recipients that does not respond well to conventional treatments for acute antibody mediated rejection (AMR).
- Trial name
- NCT07006532
- Testing
- Tocilizumab
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- Shahid Beheshti University of Medical Sciences